Pharmacogenetics describes genetic variations between individuals and their influence on the efficacy and side effects of drugs,
Pharmacogenomics examines interactions of drugs with the entire genome: changes of gene expression profiles which are caused by drugs are analysed.
The main goal of both approaches is the individual prediction of desirable and undesirable drug effects. Hence, pharmacogenetics and pharmacogenomics are contributing to improve drug treatment and to enable and support the development of drugs, which are safer, more targeted and individualized.
Genetic variability is seen both in the area of pharmacokinetics (absorption, distribution, metabolism and excretion, ADME) and in the area of pharmacodynamics (drug effects). Genetic variations may have an effect:
- on the expression of drug metabolizing enzymes,
- drug transporters or
- G-proteins.
Benefit from a comprehensive service portfolio for the entire drug development process, from preclinical research to clinical phase III trials.
Eurofins Genomics is equipped with the latest technical devices for high-throughput analysis allowing short turnaround times. Eurofins Genomics is certified according to ISO 13485 and ISO 17025 and audited by pharmaceutical clients for GxP regulations.